Cardiovascular Protection With Antihypertensive Drugs in Dialysis Patients
- 1 May 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 53 (5), 860-866
- https://doi.org/10.1161/HYPERTENSIONAHA.108.128116
Abstract
Epidemiological studies demonstrate that a lower blood pressure and decline in blood pressure over months or years are associated with higher mortality in dialysis patients. In contrast, randomized, controlled trials lack power to establish benefits of antihypertensive therapy. Patients on long-term dialysis participating in randomized, controlled trials and receiving antihypertensive drug therapy were the subject of this meta-analysis. Outcomes assessed were the hazard ratio of cardiovascular events and all-cause mortality in treated group compared with controls. Among 1202 patients who we identified in 5 studies, the overall benefit of antihypertensive therapy compared with the control or placebo group had a combined hazard ratio for cardiovascular events of 0.69 (95% CI: 0.56 to 0.84) using a fixed-effects model and 0.62 (95% CI: 0.45 to 0.86) using a random-effects model. In a sensitivity analysis, we found that the hypertensive group had a pooled hazard ratio of 0.49 (95% CI: 0.35 to 0.67), but when normotensives were included in the trial, lesser cardiovascular protection was seen (pooled hazard ratio of 0.86 [95% CI: 0.67 to 1.12]). Test for heterogeneity between hypertensive and “normotensive-included” groups was significant ( P <0.006). Similar results were seen for risk ratio for death and cardiovascular events. There was evidence of publication bias based on Egger’s test and funnel plot. Randomized trials suggested a benefit of antihypertensive therapy among hemodialysis patients. Adequately powered randomized trials are required to confirm these observations, especially among those with hypertension.Keywords
This publication has 29 references indexed in Scilit:
- Call to Action on Use and Reimbursement for Home Blood Pressure MonitoringHypertension, 2008
- Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patientsNephrology Dialysis Transplantation, 2008
- Home Blood Pressures Are of Greater Prognostic Value than Hemodialysis Unit RecordingsClinical Journal of the American Society of Nephrology, 2007
- Location Not Quantity of Blood Pressure Measurements Predicts Mortality in Hemodialysis PatientsAmerican Journal of Nephrology, 2007
- Which Targets in Clinical Practice Guidelines Are Associated with Improved Survival in a Large Dialysis Organization?Journal of the American Society of Nephrology, 2007
- Pre- and Postdialysis Blood Pressures Are Imprecise Estimates of Interdialytic Ambulatory Blood PressureClinical Journal of the American Society of Nephrology, 2006
- Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis PopulationHypertension, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trialJournal of the American College of Cardiology, 2003
- Selected major risk factors and global and regional burden of diseaseThe Lancet, 2002